VOYAGER THERAPEUTICS INC. - COMMON STOCK

Voyager Therapeutics to Present at Multiple Upcoming Investor Conferences

29 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Voyager Therapeutics to Present at Canaccord Genuity 44th Annual Growth Conference & Private Company Showcase

07 Aug 2024 07:00:00 By Nasdaq GlobeNewswire

Voyager Therapeutics Reports Second Quarter 2024 Financial and Operating Results

06 Aug 2024 16:01:00 By Nasdaq GlobeNewswire

Voyager Therapeutics Announces Second Quarter 2024 Conference Call and Webcast

30 Jul 2024 07:00:00 By Nasdaq GlobeNewswire

Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

23 Jul 2024 16:01:00 By Nasdaq GlobeNewswire

Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

09 Jul 2024 16:01:00 By Nasdaq GlobeNewswire

Voyager Therapeutics to Present at Multiple Virtual Investor Conferences

13 Jun 2024 16:01:00 By Nasdaq GlobeNewswire

Voyager Therapeutics Announces Appointment of Nathan Jorgensen as Chief Financial Officer

13 Jun 2024 07:00:00 By Nasdaq GlobeNewswire

Voyager Therapeutics Announces First Participants Dosed in Single Ascending Dose Trial of VY-TAU01 for the Treatment of Alzheimer’s Disease

16 May 2024 07:00:00 By Nasdaq GlobeNewswire

Voyager Therapeutics Reports First Quarter 2024 Financial and Operating Results

13 May 2024 16:01:00 By Nasdaq GlobeNewswire

Voyager Therapeutics Presents Data for Second-Generation, TRACER™-Generated Capsids and CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting

08 May 2024 06:00:00 By Nasdaq GlobeNewswire

Voyager Therapeutics Announces First Quarter 2024 Conference Call and Webcast

06 May 2024 07:00:00 By Nasdaq GlobeNewswire

Voyager Therapeutics to Present Broad Set of Translational Data Supporting IV-Delivered, CNS Gene Therapy Programs Advancing Toward Clinical Trials at the ASGCT 27th Annual Meeting

22 Apr 2024 16:30:00 By Nasdaq GlobeNewswire

Voyager Therapeutics Announces Selection of Development Candidate for GBA1 Program in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment

16 Apr 2024 07:00:00 By Nasdaq GlobeNewswire

Voyager Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

26 Mar 2024 16:01:00 By Nasdaq GlobeNewswire

Voyager Therapeutics Announces Appointment of Toby Ferguson as Chief Medical Officer

13 Mar 2024 07:00:00 By Nasdaq GlobeNewswire

Voyager Therapeutics Reports Fourth Quarter and Full Year 2023 Financial and Operating Results

28 Feb 2024 16:01:00 By Nasdaq GlobeNewswire

Voyager Therapeutics Announces Selection of Gene Therapy Development Candidate for Friedreich’s Ataxia in Collaboration with Neurocrine Biosciences, Triggering Milestone Payment

26 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Voyager Therapeutics Announces Fourth Quarter 2023 Conference Call and Webcast

21 Feb 2024 07:00:00 By Nasdaq GlobeNewswire

Voyager Therapeutics Reports Robust Preclinical Activity in Tau Silencing Gene Therapy Program for Alzheimer’s Disease and Advances Program into Late Research

20 Feb 2024 07:00:00 By Nasdaq GlobeNewswire